159 related articles for article (PubMed ID: 11315510)
1. In vitro characterisation of a monovalent and bivalent form of a fully human anti Ep-CAM phage antibody.
Roovers RC; van der Linden E; de Bruïne AP; Arends JW; Hoogenboom HR
Cancer Immunol Immunother; 2001 Mar; 50(1):51-9. PubMed ID: 11315510
[TBL] [Abstract][Full Text] [Related]
2. High-affinity recombinant phage antibodies to the pan-carcinoma marker epithelial glycoprotein-2 for tumour targeting.
Roovers RC; Henderikx P; Helfrich W; van der Linden E; Reurs A; de Bruïne AP; Arends JW; de Leij L; Hoogenboom HR
Br J Cancer; 1998 Dec; 78(11):1407-16. PubMed ID: 9836471
[TBL] [Abstract][Full Text] [Related]
3. A3--a novel colon and pancreatic cancer reactive antibody from a primate phage library selected using intact tumour cells.
Tordsson J; Lavasani S; Ohlsson L; Karlström P; Svedberg H; Abrahmsén L; Brodin T
Int J Cancer; 2000 Aug; 87(4):559-68. PubMed ID: 10918198
[TBL] [Abstract][Full Text] [Related]
4. Guided selection of a pan carcinoma specific antibody reveals similar binding characteristics yet structural divergence between the original murine antibody and its human equivalent.
Beiboer SH; Reurs A; Roovers RC; Arends JW; Whitelegg NR; Rees AR; Hoogenboom HR
J Mol Biol; 2000 Feb; 296(3):833-49. PubMed ID: 10677285
[TBL] [Abstract][Full Text] [Related]
5. High thermal stability is essential for tumor targeting of antibody fragments: engineering of a humanized anti-epithelial glycoprotein-2 (epithelial cell adhesion molecule) single-chain Fv fragment.
Willuda J; Honegger A; Waibel R; Schubiger PA; Stahel R; Zangemeister-Wittke U; Plückthun A
Cancer Res; 1999 Nov; 59(22):5758-67. PubMed ID: 10582696
[TBL] [Abstract][Full Text] [Related]
6. Human antibody derivatives against the fibroblast activation protein for tumor stroma targeting of carcinomas.
Mersmann M; Schmidt A; Rippmann JF; Wüest T; Brocks B; Rettig WJ; Garin-Chesa P; Pfizenmaier K; Moosmayer D
Int J Cancer; 2001 Apr; 92(2):240-8. PubMed ID: 11291052
[TBL] [Abstract][Full Text] [Related]
7. Targeting of bivalent anti-ErbB2 diabody antibody fragments to tumor cells is independent of the intrinsic antibody affinity.
Nielsen UB; Adams GP; Weiner LM; Marks JD
Cancer Res; 2000 Nov; 60(22):6434-40. PubMed ID: 11103810
[TBL] [Abstract][Full Text] [Related]
8. Specific targeting of Ep-CAM in various carcinomas by novel monoclonal antibodies.
Sithambaram D; Palanivelu S; Subramanian K; Sahoo S; Verma RS
Hybridoma (Larchmt); 2011 Dec; 30(6):511-8. PubMed ID: 22149275
[TBL] [Abstract][Full Text] [Related]
9. Characterisation of the new EpCAM-specific antibody HO-3: implications for trifunctional antibody immunotherapy of cancer.
Ruf P; Gires O; Jäger M; Fellinger K; Atz J; Lindhofer H
Br J Cancer; 2007 Aug; 97(3):315-21. PubMed ID: 17622246
[TBL] [Abstract][Full Text] [Related]
10. Vaccination with Ep-CAM protein or anti-idiotypic antibody induces Th1-biased response against MHC class I- and II-restricted Ep-CAM epitopes in colorectal carcinoma patients.
Mosolits S; Markovic K; Frödin JE; Virving L; Magnusson CG; Steinitz M; Fagerberg J; Mellstedt H
Clin Cancer Res; 2004 Aug; 10(16):5391-402. PubMed ID: 15328177
[TBL] [Abstract][Full Text] [Related]
11. Targeting of human breast cancer by a bispecific antibody directed against two tumour-associated antigens: ErbB-2 and carcinoembryonic antigen.
Dorvillius M; Garambois V; Pourquier D; Gutowski M; Rouanet P; Mani JC; Pugnière M; Hynes NE; Pèlegrin A
Tumour Biol; 2002; 23(6):337-47. PubMed ID: 12677091
[TBL] [Abstract][Full Text] [Related]
12. The biology of the 17-1A antigen (Ep-CAM).
Balzar M; Winter MJ; de Boer CJ; Litvinov SV
J Mol Med (Berl); 1999 Oct; 77(10):699-712. PubMed ID: 10606205
[TBL] [Abstract][Full Text] [Related]
13. Efficient tumor cell lysis by autologous, tumor-resident T lymphocytes in primary ovarian cancer samples by an EP-CAM-/CD3-bispecific antibody.
Wimberger P; Xiang W; Mayr D; Diebold J; Dreier T; Baeuerle PA; Kimmig R
Int J Cancer; 2003 Jun; 105(2):241-8. PubMed ID: 12673686
[TBL] [Abstract][Full Text] [Related]
14. Efficient selection of scFv antibody phage by adsorption to in situ expressed antigens in tissue sections.
Tordsson J; Abrahmsén L; Kalland T; Ljung C; Ingvar C; Brodin T
J Immunol Methods; 1997 Dec; 210(1):11-23. PubMed ID: 9502581
[TBL] [Abstract][Full Text] [Related]
15. A novel tumor-specific human single-chain Fv selected from an active specific immunotherapy phage display library.
Hall BL; Boroughs J; Kobrin BJ
Immunotechnology; 1998 Oct; 4(2):127-40. PubMed ID: 9853954
[TBL] [Abstract][Full Text] [Related]
16. Model systems to study the parameters determining the success of phage antibody selections on complex antigens.
Mutuberria R; Hoogenboom HR; van der Linden E; de Bruïne AP; Roovers RC
J Immunol Methods; 1999 Dec; 231(1-2):65-81. PubMed ID: 10648928
[TBL] [Abstract][Full Text] [Related]
17. High-throughput generation and engineering of recombinant human antibodies.
Krebs B; Rauchenberger R; Reiffert S; Rothe C; Tesar M; Thomassen E; Cao M; Dreier T; Fischer D; Höss A; Inge L; Knappik A; Marget M; Pack P; Meng XQ; Schier R; Söhlemann P; Winter J; Wölle J; Kretzschmar T
J Immunol Methods; 2001 Aug; 254(1-2):67-84. PubMed ID: 11406154
[TBL] [Abstract][Full Text] [Related]
18. Antitumor immune effector mechanisms recruited by phage display-derived fully human IgG1 and IgA1 monoclonal antibodies.
Huls G; Heijnen IA; Cuomo E; van der Linden J; Boel E; van de Winkel JG; Logtenberg T
Cancer Res; 1999 Nov; 59(22):5778-84. PubMed ID: 10582699
[TBL] [Abstract][Full Text] [Related]
19. Isolation of a high affinity scFv from a monoclonal antibody recognising the oncofoetal antigen 5T4.
Shaw DM; Embleton MJ; Westwater C; Ryan MG; Myers KA; Kingsman SM; Carroll MW; Stern PL
Biochim Biophys Acta; 2000 Dec; 1524(2-3):238-46. PubMed ID: 11113573
[TBL] [Abstract][Full Text] [Related]
20. Anti-self antibodies selected from a human IgD heavy chain repertoire: a novel approach to generate therapeutic human antibodies against tumor-associated differentiation antigens.
Raum T; Gruber R; Riethmüller G; Kufer P
Cancer Immunol Immunother; 2001 May; 50(3):141-50. PubMed ID: 11419181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
